Form 4: Corvus Pharmaceuticals Executive Acquires Shares and Warrants

William Benton Jones, SVP of Pharmaceutical Development at Corvus Pharmaceuticals, purchased 20,000 shares of common stock and acquired warrants to purchase 19,357 shares.

Summary

• William Benton Jones, a Senior Vice President at Corvus Pharmaceuticals, acquired 20,000 shares of Corvus Pharmaceuticals common stock on May 6, 2024.
• The purchase price was $1.7312 per share.
• Following the transaction, Jones directly owns 153,773 shares of Corvus Pharmaceuticals common stock.
• Jones also acquired warrants to purchase 19,357 shares of common stock with an exercise price of $3.50, expiring on June 30, 2025.
• The warrants were issued at no additional consideration in connection with the share subscription.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. An insider purchase is generally a good sign, but the amount is not significantly large.

Positives

• An executive's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely watched by investors as they can provide insights into a company's prospects. Purchases are generally viewed more favorably than sales.

Stakeholder Impact

• The stock purchase could have a slightly positive impact on shareholder sentiment.

Key Dates